Cancer treatment has evolved rapidly over the last decade. One of the most exciting advances is CAR T-cell therapy, a form of personalized immunotherapy that uses a patient’s own immune system to fight cancer.
This revolutionary treatment has transformed outcomes for some patients with difficult-to-treat blood cancers such as Acute Lymphoblastic Leukemia and Diffuse Large B‑Cell Lymphoma.
Unlike traditional chemotherapy, CAR-T therapy works by reprogramming immune cells to recognize and destroy cancer cells.
Understanding the Immune System and Cancer
The human immune system constantly patrols the body to identify infections and abnormal cells. Among the most important immune cells are T-cells, which play a central role in detecting threats.
However, cancer cells can sometimes evade detection by the immune system. Scientists developed CAR-T therapy to enhance the ability of T-cells to recognize cancer cells more effectively.
How CAR-T Cell Therapy Works
CAR-T therapy stands for Chimeric Antigen Receptor T-cell therapy. It involves several key steps.
1. Collection of Immune Cells
Doctors collect T-cells from the patient’s blood through a process called apheresis.
2. Genetic Engineering
In a specialized laboratory, scientists modify the T-cells by inserting a gene that allows them to recognize a specific protein on cancer cells, often CD19.
3. Expansion of Cells
The modified cells are multiplied until millions of CAR-T cells are produced.
4. Infusion Back into the Patient
The engineered cells are infused back into the patient, where they begin to recognize and destroy cancer cells.
Because these cells can continue to grow and function in the body, CAR-T therapy can provide long-lasting anti-cancer activity.
The First Approved CAR-T Therapy
In 2017, the U.S. Food and Drug Administration approved the first CAR-T therapy called Kymriah, developed by Novartis.
The therapy, also known scientifically as Tisagenlecleucel, was approved for:
- Children and young adults with relapsed Acute Lymphoblastic Leukemia
- Adults with certain aggressive lymphomas
This approval marked a historic moment in cancer medicine, as it was the first gene-modified cell therapy approved for cancer treatment.
Which Cancers Can CAR-T Therapy Treat?
Currently, CAR-T therapy is mainly used for certain blood cancers, including:
Leukemia
- Acute Lymphoblastic Leukemia
Lymphoma
- Diffuse Large B‑Cell Lymphoma
- Follicular Lymphoma
Research is also exploring CAR-T therapy for:
- Multiple myeloma
- Solid tumors
Scientists around the world are developing CAR-T therapies targeting different cancer markers to expand the number of cancers that can be treated.
How Effective is CAR-T Therapy?
Clinical trials published in leading journals such as the New England Journal of Medicine have shown impressive results.
In patients with relapsed leukemia or lymphoma who had limited treatment options, CAR-T therapy has produced high remission rates, with many patients achieving durable responses.
For some patients, the treatment can lead to long-term cancer control or possible cure.
Possible Side Effects
Like any powerful cancer treatment, CAR-T therapy can cause side effects.
One of the most important complications is Cytokine Release Syndrome (CRS), which occurs when immune cells become highly activated.
Symptoms may include:
- Fever
- Low blood pressure
- Breathing difficulty
- Fatigue
Doctors are trained to manage this condition, often using medications such as Tocilizumab when necessary.
Because of these risks, CAR-T therapy is performed only at specialized centers with expertise in advanced cancer care.
The Future of Cancer Treatment
CAR-T therapy is part of a new generation of treatments known as cellular and gene therapies.
These therapies aim to train the immune system to fight cancer more effectively, rather than relying only on chemotherapy or radiation.
Researchers believe that in the coming years, CAR-T therapy may expand to treat many additional cancers.
CAR-T Therapy and Cancer Care in Nepal
At Kathmandu Cancer Center, specialists in hematology and oncology are working to build advanced cellular therapy programs, including CAR-T cell therapy, to bring next-generation cancer treatments closer to patients in Nepal.
This development would reduce the need for patients to travel abroad for complex treatments such as:
- CAR-T therapy
- bone marrow transplantation
- advanced immunotherapy
These developments aim to bring world-class cancer treatment closer to patients in Nepal.
Learn More About CAR-T Therapy
If you want to understand how this treatment may help patients with leukemia or lymphoma, read our detailed guide on: